Company Overview

Innate Pharma S.A. is a clinical-stage biotechnology company focused on the discovery and development of immuno-oncology therapeutics. The company operates within the biotechnology and pharmaceutical research and development industries, with a specialization in harnessing the innate immune system to treat cancer and inflammatory diseases. Its core scientific expertise centers on natural killer (NK) cells, immune checkpoints, and antibody-based therapies designed to enhance immune-mediated tumor destruction.

Founded in 1999 as a spin-out from academic research conducted by its founders, Innate Pharma has evolved from a research-focused startup into a publicly listed biopharmaceutical company with multiple clinical-stage assets. The company is publicly traded on Euronext Paris and has American Depositary Receipts trading in the U.S. under the ticker IPHYF. Its strategic positioning is based on deep scientific know-how in innate immunity, a differentiated therapeutic approach compared to adaptive immune checkpoint inhibitors, and long-term collaborations with large pharmaceutical partners.

Business Operations

Innate Pharma’s operations are organized around the research, development, and clinical advancement of proprietary immunotherapies. The company’s primary business activities include target discovery, antibody engineering, preclinical research, and the conduct of early- and mid-stage clinical trials. Revenue generation has historically been driven primarily by collaboration and licensing agreements, milestone payments, and research funding from strategic partners rather than product sales, as the company does not yet have a commercialized product.

The company conducts most of its research and development internally, supported by proprietary antibody platforms and translational research capabilities. Key operational relationships include long-standing partnerships with AstraZeneca for multiple oncology programs and Sanofi for earlier-stage research collaborations. Innate Pharma does not rely on manufacturing as a core revenue activity and typically outsources clinical manufacturing to specialized third-party providers.

Strategic Position & Investments

Innate Pharma’s strategic direction emphasizes advancing a focused pipeline of first-in-class and best-in-class immunotherapies targeting innate immune checkpoints and tumor-associated antigens. Growth initiatives are centered on progressing lead clinical candidates, expanding indications in oncology, and leveraging partnerships to share development risk while retaining scientific involvement. The company has prioritized assets such as monoclonal antibodies targeting NK cell receptors and antibody-drug conjugate-related technologies through collaboration.

Major strategic investments include multi-program collaboration agreements with AstraZeneca, which has included equity investment, milestone-based funding, and co-development arrangements for oncology candidates. Innate Pharma does not operate as a diversified holding company and therefore does not maintain a broad portfolio of unrelated subsidiaries, but instead focuses capital allocation on internal R&D and partnered clinical development. Emerging areas of involvement include combination immunotherapy strategies and novel immune checkpoint targets beyond PD-1/PD-L1.

Geographic Footprint

Innate Pharma is headquartered in France, with its principal offices and research facilities located in Marseille. The company’s operational footprint is primarily European, but its clinical development activities are international in scope, supporting clinical trials conducted across Europe, North America, and other regions depending on study design and regulatory requirements.

Through strategic partnerships and clinical trial networks, Innate Pharma maintains an indirect presence in the United States and other major pharmaceutical markets. Its global influence is primarily driven by collaborative development programs with multinational pharmaceutical companies rather than by owned international subsidiaries or commercial operations.

Leadership & Governance

Innate Pharma is led by an executive team with experience in biotechnology, pharmaceuticals, and immunology, supported by a supervisory board structure consistent with French public company governance standards. The leadership emphasizes scientific rigor, disciplined capital allocation, and partnership-driven value creation as core elements of the company’s strategic vision.

Key executives include:

• Hervé Brailly – Co-founder and Chairman of the Supervisory Board
• Jonathan Dickinson – Chief Executive Officer
• Pierre Dodion – Chief Medical Officer
• Franck Grimaud – Chief Financial Officer
• Eric Vivier – Co-founder and President of the Scientific Advisory Board